Literature DB >> 34035742

Targeting Beta-7 Integrins for the Treatment of Inflammatory Bowel Disease.

Jesus Rivera-Nieves1.   

Abstract

Entities:  

Year:  2020        PMID： 34035742      PMCID： PMC8132642     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  Organ specificity of lymphocyte migration: mediation by highly selective lymphocyte interaction with organ-specific determinants on high endothelial venules.

Authors:  E C Butcher; R G Scollay; I L Weissman
Journal:  Eur J Immunol       Date:  1980-07       Impact factor: 5.532

Review 3.  Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.

Authors:  Jesús Rivera-Nieves
Journal:  Curr Opin Gastroenterol       Date:  2015-11       Impact factor: 3.287

4.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

Authors:  Séverine Vermeire; Sharon O'Byrne; Mary Keir; Marna Williams; Timothy T Lu; John C Mansfield; Christopher A Lamb; Brian G Feagan; Julian Panes; Azucena Salas; Daniel C Baumgart; Stefan Schreiber; Iris Dotan; William J Sandborn; Gaik W Tew; Diana Luca; Meina T Tang; Lauri Diehl; Jeffrey Eastham-Anderson; Gert De Hertogh; Clementine Perrier; Jackson G Egen; John A Kirby; Gert van Assche; Paul Rutgeerts
Journal:  Lancet       Date:  2014-05-09       Impact factor: 79.321

5.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

Review 6.  Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.

Authors:  Tamara Pérez-Jeldres; Christopher J Tyler; Joshua D Boyer; Thangaraj Karuppuchamy; Giorgos Bamias; Parambir S Dulai; Brigid S Boland; William J Sandborn; Derek R Patel; Jesús Rivera-Nieves
Journal:  Inflamm Bowel Dis       Date:  2019-01-10       Impact factor: 5.325

7.  Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Authors:  William J Sandborn; Severine Vermeire; Helen Tyrrell; Azra Hassanali; Stuart Lacey; Swati Tole; Amanda R Tatro
Journal:  Adv Ther       Date:  2020-05-22       Impact factor: 3.845
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.